肌张力障碍

参考文献

关键文献

Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013 Jun 15;28(7):863-73.全文  摘要

Tarsy D, Simon DK. Dystonia. N Engl J Med. 2006 Aug 24;355(8):818-29. 摘要

Breakefield XO, Blood AJ, Li Y, et al. The pathophysiological basis of dystonias. Nat Rev Neurosci. 2008 Mar;9(3):222-34. 摘要

Ozelius LJ, Lubarr N, Bressman SB. Milestones in dystonia. Mov Disord. 2011 May;26(6):1106-26. 摘要

Schrag A, Trimble M, Quinn N, et al. The syndrome of fixed dystonia: an evaluation of 103 patients. Brain. 2004 Oct;127(Pt 10):2360-72.全文  摘要

Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology. 1991 Feb;41(2 ( Pt 1)):174-81. 摘要

Bhidayasiri R, Tarsy D. Treatment of dystonia. Exp Rev Neurotherap. 2006 Jun;6(6):863-86. 摘要

Kupsch A, Benecke R, Müller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med. 2006 Nov 9;355(19):1978-90.全文  摘要

Jankovic J. Treatment of dystonia. Lancet Neurol. 2006 Oct;5(10):864-72. 摘要

参考文献

1. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013 Jun 15;28(7):863-73.全文  摘要

2. Tarsy D, Simon DK. Dystonia. N Engl J Med. 2006 Aug 24;355(8):818-29. 摘要

3. Defazio G, Abbruzzese G, Livrea P, et al. Epidemiology of primary dystonia. Lancet Neurol. 2004 Nov;3(11):673-8. 摘要

4. Liu X, Luo X, Hu W. Studies on the epidemiology and etiology of moldy sugarcane poisoning in China. Biomed Environ Sci. 1992 Jun;5(2):161-77. 摘要

5. Muller J, Kiechl S, Wenning GK, et al. The prevalence of primary dystonia in the general community. Neurology. 2002 Sep 24;59(6):941-3. 摘要

6. Nutt JG, Muenter MD, Aronson A, et al. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord. 1988;3(3):188-94. 摘要

7. Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. J Neurol. 2000 Oct;247(10):787-92. 摘要

8. Albanese A. Dystonia: clinical approach. Parkinsonism Relat Disord. 2007;13 Suppl 3:S356-61. 摘要

9. Breakefield XO, Blood AJ, Li Y, et al. The pathophysiological basis of dystonias. Nat Rev Neurosci. 2008 Mar;9(3):222-34. 摘要

10. Jankovic J. Dystonia: medical therapy and botulinum toxin. Adv Neurol. 2004;94:275-86. 摘要

11. Ozelius LJ. Update on the genetics of primary torsion dystonia loci DYT6, DYT7, and DYT13 and the dystonia-plus locus DYT12. Adv Neurol. 2004;94:109-12. 摘要

12. Hallett M. Dystonia: abnormal movements result from loss of inhibition. Adv Neurol. 2004;94:1-9. 摘要

13. Ozelius LJ, Lubarr N, Bressman SB. Milestones in dystonia. Mov Disord. 2011 May;26(6):1106-26. 摘要

14. Lohmann K, Klein C. Update on the genetics of dystonia. Curr Neurol Neurosci Rep. 2017 Mar;17(3):26. 摘要

15. Schrag A, Trimble M, Quinn N, et al. The syndrome of fixed dystonia: an evaluation of 103 patients. Brain. 2004 Oct;127(Pt 10):2360-72.全文  摘要

16. Jankovic J. Can peripheral trauma induce dystonia and other movement disorders? Yes! Mov Disord. 2001 Jan;16(1):7-12. 摘要

17. van Hilten JJ, Geraedts EJ, Marinus J. Peripheral trauma and movement disorders. Parkinsonism Relat Disord. 2007;13 Suppl 3:S395-9. 摘要

18. Weiner WJ. Can peripheral trauma induce dystonia? No! Mov Disord. 2001 Jan;16(1):13-22. 摘要

19. Bressman SB, Sabatti C, Raymond D, et al. The DYT1 phenotype and guidelines for diagnostic testing. Neurology. 2000 May 9;54(9):1746-52. 摘要

20. van Egmond ME, Kuiper A, Eggink H, et al. Dystonia in children and adolescents: a systematic review and a new diagnostic algorithm. J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):774-81. 摘要

21. Jinnah HA, Factor SA. Diagnosis and treatment of dystonia. Neurol Clin. 2015 Feb;33(1):77-100.全文  摘要

22. Jinnah HA, Hess EJ. Evolving concepts in the pathogenesis of dystonia. Parkinsonism Relat Disord. 2018 Jan;46 Suppl 1:S62-5.全文  摘要

23. Armstrong M, Daly AK, Blennerhassett R, et al. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry. 1997 Jan;170:23-6. 摘要

24. Dressler D, Benecke R. Diagnosis and management of acute movement disorders. J Neurol. 2005 Nov;252(11):1299-306. 摘要

25. Rodnitzky RL. Drug-induced movement disorders in children. Semin Pediatr Neurol. 2003 Mar;10(1):80-7. 摘要

26. Laihinen A, Halsband U. PET imaging of the basal ganglia. J Physiol Paris. 2006 Jun;99(4-6):406-13. 摘要

27. Toma K, Nakai T. Functional MRI in human motor control studies and clinical applications. Magn Reson Med Sci. 2002 Jul 1;1(2):109-20. 摘要

28. Greene P, Kang UJ, Fahn S. Spread of symptoms in idiopathic torsion dystonia. Mov Disord. 1995 Mar;10(2):143-52. 摘要

29. Bonanni L, Thomas A, Varanese S, et al. Botulinum toxin treatment of lateral axial dystonia in Parkinsonism. Mov Disord. 2007 Oct 31;22(14):2097-103. 摘要

30. Bragg DC, Sharma N. Update on treatments for dystonia. Curr Neurol Neurosci Rep. 2014 Jun;14(6):454.全文  摘要

31. Segawa M. Autosomal dominant GTP cyclohydrolase I (AD GCH 1) deficiency (Segawa disease, dystonia 5; DYT 5). Chang Gung Med J. 2009 Jan-Feb;32(1):1-11.全文  摘要

32. Greene PE, Frucht SJ. Tardive and neuroleptic-induced emergencies. In: Frucht SJ, Fahn S, eds. Movement disorder emergencies. Totowa, NJ: Humana Press; 2005:117-22.

33. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011 Jan;18(1):5-18.全文  摘要

34. Burke RE, Fahn S, Marsden CD, et al. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology. 1985 Jan;35(1):73-7. 摘要

35. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York, NY: Marcel Dekker, Inc.; 1994:211-37.

36. Saunders-Pullman R, Soto-Valencia J, Costan-Toth C, et al. A new screening tool for cervical dystonia. Neurology. 2005 Jun 28;64(12):2046-9. 摘要

37. Queensland Ambulance Service. Medical/acute dystonic reaction. Apr 2016 [internet publication].全文

38. Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology. 1991 Feb;41(2 ( Pt 1)):174-81. 摘要

39. Nygaard TG, Marsden CD, Duvoisin RC. Dopa-responsive dystonia. Adv Neurol. 1988;50:377-84. 摘要

40. Bandmann O, Nygaard TG, Surtees R, et al. Dopa-responsive dystonia in British patients: new mutations of the GTP-cyclohydrolase I gene and evidence for genetic heterogeneity. Hum Mol Genet. 1996 Mar;5(3):403-6.全文  摘要

41. Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology. 1986 Feb;36(2):160-4. 摘要

42. Bhidayasiri R, Tarsy D. Treatment of dystonia. Exp Rev Neurotherap. 2006 Jun;6(6):863-86. 摘要

43. Greene P. Baclofen in the treatment of dystonia. Clin Neuropharmacol. 1992 Aug;15(4):276-88. 摘要

44. Roubertie A, Mariani LL, Fernandez-Alvarez E, et al. Treatment for dystonia in childhood. Eur J Neurol. 2012 Oct;19(10):1292-9. 摘要

45. Butler C, Campbell S. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. AACPDM Treatment Outcomes Committee Review Panel. Dev Med Child Neurol. 2000 Sep;42(9):634-45.全文  摘要

46. Hainque E, Vidailhet M, Cozic N, et al. A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. Neurology. 2016 May 3;86(18):1729-35. 摘要

47. Zoons E, Dijkgraaf MG, Dijk JM, et al. Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. J Neurol. 2012 Dec;259(12):2519-26.全文  摘要

48. Charles D, Brashear A, Hauser RA, et al. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clinic Neuropharmacol. 2012 Sep-Oct;35(5):208-14. 摘要

49. Colosimo C, Tiple D, Berardelli A. Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res. 2012 Nov;22(4):265-73. 摘要

50. Marques RE, Duarte GS, Rodrigues FB, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2016 May 13;(5):CD004315.全文  摘要

51. Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 May 6;70(19):1699-706.全文  摘要

52. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 Apr 18;86(19):1818-26.全文  摘要

53. Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, et al. Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry. 2007 Mar;78(3):264-70.全文  摘要

54. Jankovic J. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol. 2009 Dec;16 Suppl 2:14-8. 摘要

55. Pappert EJ, Germanson T; Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008 Mar 15;23(4):510-7. 摘要

56. Delnooz CC, Horstink MW, Tijssen MA, et al. Paramedical treatment in primary dystonia: a systematic review. Mov Disord. 2009 Nov 15;24(15):2187-98. 摘要

57. Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med. 2005 Feb 3;352(5):459-67.全文  摘要

58. Kupsch A, Benecke R, Müller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med. 2006 Nov 9;355(19):1978-90.全文  摘要

59. Kiss ZH, Doig-Beyaert K, Eliasziw M, et al. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain. 2007 Nov;130(Pt 11):2879-86.全文  摘要

60. Mueller J, Skogseid IM, Benecke R, et al. Pallidal deep brain stimulation improves quality of life in segmental and generalized dystonia: results from a prospective, randomized sham-controlled trial. Mov Disord. 2008 Jan;23(1):131-4. 摘要

61. Volkmann J, Mueller J, Deuschl G, et al. Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol. 2014 Sep;13(9):875-84. 摘要

62. DiFrancesco MF, Halpern CH, Hurtig HH, et al. Pediatric indications for deep brain stimulation. Childs Nerv Syst. 2012 Oct;28(10):1701-14. 摘要

63. Isaias IU, Alterman RL, Tagliati M. Outcome predictors of pallidal stimulation in patients with primary dystonia: the role of disease duration. Brain. 2008 Jul;131(Pt 7):1895-902.全文  摘要

64. Krauss JK, Loher TJ, Weigel R, et al. Chronic stimulation of the globus pallidus internus for treatment of non-dYT1 generalized dystonia and choreoathetosis: 2-year follow up. J Neurosurg. 2003 Apr;98(4):785-92. 摘要

65. Starr PA, Turner RS, Rau G, et al. Microelectrode-guided implantation of deep brain stimulators into the globus pallidus internus for dystonia: techniques, electrode locations, and outcomes. J Neurosurg. 2006 Apr;104(4):488-501. 摘要

66. Andrews C, Aviles-Olmos I, Hariz M, et al. Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes. J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1383-9. 摘要

67. Bronte-Stewart H, Taira T, Valldeoriola F, et al. Inclusion and exclusion criteria for DBS in dystonia. Mov Disord. 2011 Jun;26 Suppl 1:S5-16. 摘要

68. Yoshor D, Hamilton WJ, Ondo W, et al. Comparison of thalamotomy and pallidotomy for the treatment of dystonia. Neurosurgery. 2001 Apr;48(4):818-24. 摘要

69. Molina-Negro P, Bouvier G. Surgical treatment of spasmodic torticollis by peripheral denervation. In: Tarsy D, Vitek JL, Lozano AM, eds. Surgical treatment of Parkinson's disease and other movement disorders. Totowa, NJ: Humana Press; 2003:275-86.

70. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol. 1982 Jan;11(1):41-7. 摘要

71. Paleacu D, Giladi N, Moore O, et al. Tetrabenazine treatment in movement disorders. Clin Neuropharmacol. 2004 Sep-Oct;27(5):230-3. 摘要

72. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. 2017 Apr 26;88(21):2003-10.全文  摘要

73. Touma KT, Scarff JR. Valbenazine and deutetrabenazine for tardive dyskinesia. Innov Clin Neurosci. 2018 Jun 1;15(5-6):13-6. 摘要

74. Chen JJ. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clinical Therapeutics. 2012 Jul;34(7):1487-504. 摘要

75. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017 Jun 28;4(8):595-604. 摘要

76. Frank S, Testa CM, Stamler D, et al; Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016 Jul 5;316(1):40-50.全文  摘要

77. Goff DC, Arana GW, Greenblatt DJ, et al. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol. 1991 Apr;11(2):106-12. 摘要

78. Chawda SJ, Münchau A, Johnson D, et al. Pattern of premature degenerative changes of the cervical spine in patients with spasmodic torticollis and the impact on the outcome of selective peripheral denervation. J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):465-71.全文  摘要

79. Sanger TD. Use of surface electromyography (EMG) in the diagnosis of childhood hypertonia: a pilot study. J Child Neurol. 2008 Jun;23(6):644-8. 摘要

80. Jankovic J. Treatment of dystonia. Lancet Neurol. 2006 Oct;5(10):864-72. 摘要

81. Brin MF, Comella C, Jankovic J. Dystonia: etiology, clinical features, and treatment. Philadelphia, PA: Lippincott Williams & Williams; 2004:45-9.

内容使用需遵循免责声明